J&J JNJ-6143 Prostate Cancer Trial: 77% PSA Response in Early Study
The J&J JNJ-6143 prostate cancer pill cut PSA by 50% or more in 77% of patients in a Phase 1 trial. Data, safety and why reported figures differ.
The J&J JNJ-6143 prostate cancer pill cut PSA by 50% or more in 77% of patients in a Phase 1 trial. Data, safety and why reported figures differ.